96 related articles for article (PubMed ID: 29768183)
1. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
2. The role of Bcl-x(L) protein in nucleotide excision repair-facilitated cell protection against cisplatin-induced apoptosis.
Lomonaco SL; Xu XS; Wang G
DNA Cell Biol; 2009 Jun; 28(6):285-94. PubMed ID: 19317621
[TBL] [Abstract][Full Text] [Related]
3. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells.
Tsai CM; Chang KT; Li L; Perng RP; Yang LY
Jpn J Cancer Res; 2000 Feb; 91(2):213-22. PubMed ID: 10761709
[TBL] [Abstract][Full Text] [Related]
4. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
5. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality.
Simon GR; Ismail-Khan R; Bepler G
Int J Biochem Cell Biol; 2007; 39(7-8):1318-28. PubMed ID: 17600754
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of DNA repair nuclease ERCC1-XPF promotes prostate cancer progression in a tissue recombination model.
Matoka DJ; Yao V; Harya DS; Gregg JL; Robinson AR; Niedernhofer LJ; Parwani AV; Maier C; Bacich DJ
Prostate; 2012 Aug; 72(11):1214-22. PubMed ID: 22212909
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.
Balin-Gauthier D; Delord JP; Pillaire MJ; Rochaix P; Hoffman JS; Bugat R; Cazaux C; Canal P; Allal BC
Br J Cancer; 2008 Jan; 98(1):120-8. PubMed ID: 18182978
[TBL] [Abstract][Full Text] [Related]
9. Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Bowden NA; Ashton KA; Vilain RE; Avery-Kiejda KA; Davey RJ; Murray HC; Budden T; Braye SG; Zhang XD; Hersey P; Scott RJ
PLoS One; 2013; 8(8):e70424. PubMed ID: 23940574
[TBL] [Abstract][Full Text] [Related]
10. Single-Cell Transcriptome Analysis Uncovers Intratumoral Heterogeneity and Underlying Mechanisms for Drug Resistance in Hepatobiliary Tumor Organoids.
Zhao Y; Li ZX; Zhu YJ; Fu J; Zhao XF; Zhang YN; Wang S; Wu JM; Wang KT; Wu R; Sui CJ; Shen SY; Wu X; Wang HY; Gao D; Chen L
Adv Sci (Weinh); 2021 Jun; 8(11):e2003897. PubMed ID: 34105295
[TBL] [Abstract][Full Text] [Related]
11. Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamics.
Yang Y; Liu L; Tian Y; Gu M; Wang Y; Ashrafizadeh M; Reza Aref A; Cañadas I; Klionsky DJ; Goel A; Reiter RJ; Wang Y; Tambuwala M; Zou J
Cancer Lett; 2024 Apr; 587():216659. PubMed ID: 38367897
[TBL] [Abstract][Full Text] [Related]
12. E2F8-CENPL pathway contributes to homologous recombination repair and chemoresistance in breast cancer.
Wang S; Xia Y; Sun Y; Wang W; Shan L; Zhang Z; Zhao C
Cell Signal; 2024 Jun; 118():111151. PubMed ID: 38522807
[TBL] [Abstract][Full Text] [Related]
13. Effect of CMNa combined with radiotherapy on the tumor immune microenvironment of mouse cervical cancer cell transplantation tumor model.
Li L; Shi W; Zhou J
Bioengineered; 2021 Dec; 12(1):1066-1077. PubMed ID: 33784955
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues.
Yang Y; Adebali O; Wu G; Selby CP; Chiou YY; Rashid N; Hu J; Hogenesch JB; Sancar A
Proc Natl Acad Sci U S A; 2018 May; 115(21):E4777-E4785. PubMed ID: 29735688
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer.
Liu J; Zhang L; Mao P; Jiang G; Liu L; Wang J; Yang W; Owusu L; Li W
Oncotarget; 2017 Oct; 8(49):85759-85771. PubMed ID: 29156754
[TBL] [Abstract][Full Text] [Related]
16. NDRG1 Downregulates ATF3 and Inhibits Cisplatin-Induced Cytotoxicity in Lung Cancer A549 Cells.
Du A; Jiang Y; Fan C
Int J Med Sci; 2018; 15(13):1502-1507. PubMed ID: 30443171
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity.
Ye T; Lin A; Qiu Z; Hu S; Zhou C; Liu Z; Cheng Q; Zhang J; Luo P
iScience; 2023 Jul; 26(7):107045. PubMed ID: 37448561
[TBL] [Abstract][Full Text] [Related]
18. NDRG1 in Cancer: A Suppressor, Promoter, or Both?
Joshi V; Lakhani SR; McCart Reed AE
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497221
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted and Intricate Oncogenic Mechanisms of NDRG1 in Head and Neck Cancer Depend on Its C-Terminal 3R-Motif.
You GR; Chang JT; Li HF; Cheng AJ
Cells; 2022 May; 11(9):. PubMed ID: 35563887
[TBL] [Abstract][Full Text] [Related]
20. Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy.
Guerriero I; Monaco G; Coppola V; Orlacchio A
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33266470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
